ILTOO Pharma SAS today announced the results of MIROCALS, a Phase IIb trial in amyotrophic lateral sclerosis (ALS) using low-dose Interleukine-2 (IL-2LD), which were presented by Dr. Gilbert Bensimon
at the International Symposium on ALS / Motor Neuron Diseases.